ipragliflozin (sublet) Report issue

Small molecule Experimental
AACT DrugBank Drug Central MeSH PubChem

Active Ingredient History

NOW
  • Now
Ipragliflozin is a pharmaceutical drug for treatment of type 2 diabetes. Ipragliflozin, jointly developed by Astellas Pharma and Kotobuki Pharmaceutical, was approved in Japan on January 17, 2014, and in Russia on May 22, 2019.   Wikipedia

Chemistry

  • SMILES: OC[C@H]1O[C@@H](c2ccc(F)c(Cc3cc4ccccc4s3)c2)[C@H](O)[C@@H](O)[C@@H]1O
  • InChIKey: AHFWIQIYAXSLBA-RQXATKFSSA-N
  • Mol. Mass: 404.46
  • ALogP: 2.15
  • ChEMBL Molecule:
    ipragliflozin  
More Chemistry

Pharmacology

Alternative names

asp1941 | ipragliflozin | ipragliflozin l-proline | suglat

Organizations (7)

Research & Development (7)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (9)

Approved Indications (1)


 

Diabetes Mellitus, Type 2

Experimental Indications - Clinical Trial Phases 1-4 (9)


 

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 1 (Phase 3)

Diabetes Mellitus, Type 2 (Phase 4)

Drugs, Investigational (Phase 1)

Healthy Volunteers (Phase 1)

Heart Diseases (Phase 1)

Liver Diseases (Phase 1)

Pharmacokinetics (Phase 1)

Pharmacology (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 51
  • # of Trial Organizations: 7

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue